Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.39 |
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | WNT1 | P04628 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3385349 | 0.90 | HRH3 (0.44) | KDRHRH3ACACBDRD3 | |
| SCHEMBL3386245 | 0.84 | HRH3 (0.56) | HRH3SCN9A | |
| SCHEMBL3387535 | 0.83 | HRH3 (0.40) | HRH3ACACBTIPARPDRD3 | |
| SCHEMBL3384823 | 0.83 | HRH3 (0.44) | KDRHRH3ACACBTIPARPDRD3 | |
| SCHEMBL3930338 | 0.82 | HRH3 (0.54) | KDRHRH3ACACBTIPARPDRD3 | |
| SCHEMBL4421814 | 0.82 | KDR (0.39) | KDRHRH3ACACBTIPARPNAMPT | |
| SCHEMBL118339 | 0.77 | HRH3 (0.54) | HRH3 | |
| SCHEMBL3385288 | 0.76 | HRH3 (0.40) | HRH3TIPARP | |
| SCHEMBL986213 | 0.74 | HRH3 (0.46) | HRH3TIPARP | |
| SCHEMBL3921304 | 0.74 | PARP1 (0.36) | HRH3TIPARP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557121-B2 | Tetrahydronaphthyridine derivatives | PFIZER INC (US) | 2009-07-07 | — | — | US | disclosed |
| US-20050256135-A1 | Tetrahydronaphthyridine derivatives | LUNN GRAHAM | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256135-A1 | Tetrahydronaphthyridine derivatives | HRH4, HRH3, HRH1 | KDR 3079/4885HRH3 2/4885ACACB 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.